Targeting MCL-1 in cancer: current status and perspectives.
Haolan WangMing GuoHudie WeiYongheng ChenPublished in: Journal of hematology & oncology (2021)
Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The central role of MCL-1 in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Significant progress has been made with regard to MCL-1 inhibitors, some of which have entered clinical trials. Here, we discuss the mechanism by which MCL-1 regulates cancer cell apoptosis and review the progress related to MCL-1 small molecule inhibitors and their role in cancer therapy.
Keyphrases
- cancer therapy
- poor prognosis
- small molecule
- cell death
- clinical trial
- papillary thyroid
- drug delivery
- oxidative stress
- acute myeloid leukemia
- long non coding rna
- current status
- bone marrow
- cell proliferation
- transcription factor
- protein protein
- squamous cell carcinoma
- immune response
- mouse model
- signaling pathway
- young adults
- drug induced
- lymph node metastasis
- binding protein
- cell cycle arrest
- phase ii